Schizophrenia
Conditions
Keywords
schizophrenia, Ginkgo biloba extract, cognition
Brief summary
We investigated the effects of Ginkgo biloba extract on the symptoms and cognitive functioning in patients with schizophrenia
Detailed description
Objective: This study aimed to evaluate the effect of Ginkgo biloba extract in the treatment of symptoms and cognitive functioning in 200? chronic patients with schizophrenia Methods: 1. Clinical Trial: This is a randomized, double-blind and parallel controlled trial in the chronic patients with schizophrenia. The study consists of 12 weeks of double-blind treatment. 2. Assessment Procedures: 2.1 Primary Outcome Variable: Patients were assessed by two clinical trained staff, who were blind to the treatment protocols, by using the Positive and Negative Syndrome Scale (PANSS) to assess the psychopathology and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) to evaluation the cognitive functioning. Patients were interviewed at screening, and at baseline, 4? weeks, 12? weeks. 2.2 Side effects: The side effect rating scale (UKU) was used to assess the side effect at baseline, 4? weeks, and 12? weeks. 2.3 Weight gain measurement: weigh was measured every week.
Interventions
Ginkgo biloba extract with 360mg was administered
DRUGPlacebo oral tablet
Placebo with nine tables was administered
Sponsors
Beijing HuiLongGuan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Diagnosis of schizophrenia by two senior psychiatrists * Between 18 and 60 years and Han Chinese * Duration of symptoms at least 12 months * Current psychotic symptoms of moderate severity
Exclusion criteria
* A Diagnostic and Statistical Manual of Mental Disorders IV Axis I diagnosis other than schizophrenia * Documented disease of physical diseases including, but not limited to stroke, tumor, Parkinson's disease, Huntington's disease, seizure, epilepsy, history of brain trauma； * Pregnant or breast-feeding female' * Subjects who suffered from alcohol or illegal durg abuse/dependence
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| clinical symptoms | 12 weeks | symptoms assessed on PANSS |
| cognitive functioning | 12 weeks | cognitive functioning assessed on RBANS |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Side effects | 12 weeks | side effect assessed on UKU |
Countries
China
Outcome results
None listed